![Mapping the immune environment in clear cell renal carcinoma by single-cell genomics | Communications Biology Mapping the immune environment in clear cell renal carcinoma by single-cell genomics | Communications Biology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs42003-020-01625-6/MediaObjects/42003_2020_1625_Fig1_HTML.png)
Mapping the immune environment in clear cell renal carcinoma by single-cell genomics | Communications Biology
![Prediction of drug candidates for clear cell renal cell carcinoma using a systems biology-based drug repositioning approach - eBioMedicine Prediction of drug candidates for clear cell renal cell carcinoma using a systems biology-based drug repositioning approach - eBioMedicine](https://www.thelancet.com/cms/attachment/efeb09d3-4d87-4860-b235-6798c71171ce/gr1_lrg.jpg)
Prediction of drug candidates for clear cell renal cell carcinoma using a systems biology-based drug repositioning approach - eBioMedicine
![Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma | Journal of Experimental & Clinical Cancer Research Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma | Journal of Experimental & Clinical Cancer Research](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13046-021-02026-1/MediaObjects/13046_2021_2026_Fig5_HTML.png)
Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma | Journal of Experimental & Clinical Cancer Research
![Cancers | Free Full-Text | From Immunohistochemistry to New Digital Ecosystems: A State-of-the-Art Biomarker Review for Precision Breast Cancer Medicine Cancers | Free Full-Text | From Immunohistochemistry to New Digital Ecosystems: A State-of-the-Art Biomarker Review for Precision Breast Cancer Medicine](https://www.mdpi.com/cancers/cancers-14-03469/article_deploy/html/images/cancers-14-03469-g001.png)
Cancers | Free Full-Text | From Immunohistochemistry to New Digital Ecosystems: A State-of-the-Art Biomarker Review for Precision Breast Cancer Medicine
![Novel Liquid Biomarkers and Innovative Imaging for Kidney Cancer Diagnosis: What Can Be Implemented in Our Practice Today? A Systematic Review of the Literature - ScienceDirect Novel Liquid Biomarkers and Innovative Imaging for Kidney Cancer Diagnosis: What Can Be Implemented in Our Practice Today? A Systematic Review of the Literature - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2588931120302194-gr1.jpg)
Novel Liquid Biomarkers and Innovative Imaging for Kidney Cancer Diagnosis: What Can Be Implemented in Our Practice Today? A Systematic Review of the Literature - ScienceDirect
![miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review: Molecular Therapy - Nucleic Acids miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review: Molecular Therapy - Nucleic Acids](https://www.cell.com/cms/attachment/874c5ab3-341d-4a5b-be50-e751a71db328/fx1_lrg.jpg)
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review: Molecular Therapy - Nucleic Acids
![Frontiers | IFI16 Can Be Used as a Biomarker for Diagnosis of Renal Cell Carcinoma and Prediction of Patient Survival Frontiers | IFI16 Can Be Used as a Biomarker for Diagnosis of Renal Cell Carcinoma and Prediction of Patient Survival](https://www.frontiersin.org/files/MyHome%20Article%20Library/599952/599952_Thumb_400.jpg)
Frontiers | IFI16 Can Be Used as a Biomarker for Diagnosis of Renal Cell Carcinoma and Prediction of Patient Survival
![Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma | Journal of Experimental & Clinical Cancer Research Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma | Journal of Experimental & Clinical Cancer Research](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13046-021-02026-1/MediaObjects/13046_2021_2026_Fig1_HTML.png)
Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma | Journal of Experimental & Clinical Cancer Research
![Biomarkers in renal cell carcinoma: Towards a more selective immune checkpoint inhibition - ScienceDirect Biomarkers in renal cell carcinoma: Towards a more selective immune checkpoint inhibition - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1936523321000632-fx1.jpg)
Biomarkers in renal cell carcinoma: Towards a more selective immune checkpoint inhibition - ScienceDirect
![Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma - ScienceDirect Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1535610821001173-fx1.jpg)